Ebola Hemorrhagic Fever in Kikwit, Democratic Republic of the Congo: Clinical Observations in 103 Patients

Abstract

During the 1995 outbreak of Ebola hemorrhagic fever in the Democratic Republic of the Congo, a series of 103 cases (one-third of the total number of cases) had clinical symptoms and signs accurately recorded by medical workers, mainly in the setting of the urban hospital in Kikwit. Clinical diagnosis was confirmed retrospectively in cases for which serum samples were available (n = 63, 61% of the cases). The disease began unspecifically with fever, asthenia, diarrhea, headaches, myalgia, arthralgia, vomiting, and abdominal pain. Early inconsistent signs and symptoms included conjunctival injection, sore throat, and rash. Overall, bleeding signs were observed in <45% of the cases. Typically, terminally ill patients presented with obtundation, anuria, shock, tachypnea, and normothermia. Late manifestations, most frequently arthralgia and ocular diseases, occurred in convalescent patients. This series is the most extensive number of cases of Ebola hemorrhagic fever observed during an outbreak.

Neurological Complications of Ebola Virus Infection

“…In severe cases, coma may occur [18]. Meningitis and encephalitis related to EVD have also been reported in the recent outbreak, as well as in prior outbreaks, although the incidence is not well documented [22][23][24]. During acute EVD, seizures have also been reported, although these are not well characterized [11].…”

Quantifying the epidemic spread of Ebola virus (EBOV) in Sierra Leone using phylodynamics

“…While we used the conservative median value for S, we cannot exclude the possibility that most transmission remained among much smaller communities, leading to over-estimation in the number of infections by our model. Our model also does not account for an exposed stage (individuals who are infected but not yet infectious, »2 to 21 days 13 ), which would act to slow disease spread. The simpler model may artificially drive down our estimate of R 0 , particularly if incubation periods are closer to the longer end of the range.…”

A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine

“…To date, no FDAapproved vaccines or therapeutics are available for EBOV or MARV and with fatality rates as high as 90% (3,4), these viruses are classified as category A pathogens by the NIH. The EBOV genome encodes seven genes that can express eight proteins, which include: nucleoprotein (NP), VP24, VP30, VP35 and L protein, which together constitute the nucleocapsid (NC) (5); the viral-surface glycoprotein GP, a secreted glycoprotein sGP, and the viral matrix protein VP40.…”